Analytical and clinical validation of a genome sequencing-based comprehensive rare disease genomic profiling test.
Sriram, S.; Lee, S.-Y.; Ferguson, S.; Koh, J. Y.; Wallace, J. K.; Lee, J.; Kim, J.-A.; Lee, Y.; Oh, B.-L.; Lee, W. C.; Lee, S.; Connolly-Strong, E. C.
Show abstract
This study evaluates the performance of the RareVision Whole Genome Sequencing (WGS) assay for comprehensive genomic profiling in rare genetic diseases. The analytical validation assessed the assays sensitivity and positive predictive values (PPV) for single nucleotide variants (SNVs), insertions/deletions (indels), and structural variants (SVs), revealing a sensitivity of 99.4% for SNVs and 98.7% for indels, with PPVs of 99.3% for SNVs and 98.7% for indels. Clinical validation involved benchmarking against established orthogonal methods, demonstrating high concordance in variant detection with reference laboratories. The assays reproducibility was confirmed with 100% inter-precision and intra-precision concordance. The RareVision WGS assay provides detailed genomic insights, enhancing the diagnosis and management of rare genetic disorders by offering a comprehensive and accurate genomic profiling tool.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.